基于“肠-肝轴”研究疏肝理脾方对非酒精性脂肪性肝病大鼠肝脏及肠道病理结构的影响

张茜茜; 江澄; 刘玉娟; 代静; 张涛

doi:10.3969/j.issn.1671-038X.2021.06.01

基于“肠-肝轴”研究疏肝理脾方对非酒精性脂肪性肝病大鼠肝脏及肠道病理结构的影响

- 1. 湖南中医药大学第一附属医院肝病科/感染性疾病科(长沙, 410007);
- 2. 湖南中医药大学;
- 3. 江西省中西医结合医院急诊科;
- 4. 临沧市中医院内科
基金项目:
湖南省自然科学基金(No:2018JJ6039)

湖南省中医药科研计划项目(No:201823)

详细信息

通讯作者: 张涛,E-mail:9087958@qq.com

中图分类号: R575.1

收稿日期: 2020-12-17

Effect of Shugan Lipi decoction on liver and intestinal pathological structure of NASH rats based on "gut liver axis"

- 1. Department of Hepatology/Department of Infectious Disease, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, 410007, China;
- 2. Hunan University of Traditional Chinese Medicine;
- 3. Department of Emergency, Jiangxi Integrated Traditional Chinese and Western Medicine Hospital;
- 4. Department of Internal Medicine, Lincang Hospital of Traditional Chinese Medicine

More Information

Corresponding author: ZHANG Tao, E-mail: 9087958@qq.com

Received Date: 17 December 2020

摘要

摘要: 目的:研究疏肝理脾方对非酒精性脂肪性肝病(NASH)模型大鼠肝脏及肠道病理结构的影响。方法:SD雄性大鼠共50只,正常对照组(M0组)10只,一直予以普通饲料;实验组40只,开始予以蛋氨酸及胆碱缺乏饲料(MCD)饮食,8周后随机分成4组,其中2组继续饮食并予以中药干预,中药高剂量(D高组)、低剂量(D低组);另外2组无中药干预,分别继续予MCD饮食(M1组)和普通饲料(M2组)。计算肝组织炎症活动、脂肪变性及纤维化评分(SAF评分);分析比较肠微绒毛长度及宽度、肝脏脂肪变性程度。结果:与M0组比较,其余4组肠微绒毛长度均明显短缩(P<0.05);M1组、D低组、D高组肠微绒毛长度依次增加(P<0.05)。与M0组比较,其余4组肝脂肪变明显,且肝脏SFA评分均升高(P<0.05);M1组、M2组、D低组小叶间炎症个数增加,且均有不同程度的气球样变及肝纤维化(P<0.05);D高组较D低组SFA评分、脂肪变及气球样变程度更低(P<0.05)。结论:NASH大鼠肠微绒毛长度变短,疏肝健脾方可使微绒毛长度增加,其中高剂量组最优。疏肝健脾方可减轻NASH大鼠肝脏损伤程度,且高剂量组降低脂肪变、气球样变及SFA评分更明显。
- 非酒精性脂肪性肝炎 /
- 肠-肝轴 /
- 肠黏膜 /
- 超微结构
Abstract: Objective: To study the effects of Shugan Lipi decoction on the pathological structure of liver and intestine in rats with NASH induced by MCD diet.Methods: A total of 50 SPF SD male rats were given MCD diet in experimental group(n=40). Normal control group(M0 group) 10 rats were given normal diet. After 8 weeks of feeding, the experimental group was randomly divided into 4 groups, two of which were treated with Chinese Medicine intervention and continued with MCD diet, and then divided into low-dose Chinese Medicine(D low group) and high-dose Chinese medicine(D high group). The other two groups were the control group without Traditional Chinese Medicine intervention, and were continued to receive MCD diet(group M1) and normal feed(group M2), respectively. Inflammatory activity, steatosis and fibrosis score(SAF score) of liver tissue were calculated. The length and width of intestinal microvilli and the degree of hepatic steatosis were compared.Results: Compared with M0 group, the length of intestinal microvilli in the other four groups were significantly shorter(P<0.05); the length of intestinal microvilli in M1 group, D low group and d high group increased in turn(P<0.05). Compared with the M0 group, the other four groups had obvious liver steatosis and increased liver SFA score(P<0.05); the number of interlobular inflammation increased in M1 group, M2 group and D low group, and there were different degrees of ballooning degeneration and liver fibrosis(P<0.05); the SFA score, steatosis and balloon degeneration in D high group were lower than those in low D group(P<0.05); the number of interlobular inflammation and the degree of liver fibrosis in D high group and D low group were lower(P<0.05).Conclusion: The length of intestinal microvilli in NASH rats becomes shorter, and Shugan Jianpi decoction can increase the length of intestinal microvilli, and the high-dose group is the best. Shugan Jianpi decoction can reduce the degree of liver injury in NASH rats, and the high-dose group can reduce fatty degeneration, ballooning change and SFA score more significantly.
- nonalcoholic steatohepatitis /
- gut-liver axis /
- intestinal mucosa /
- ultrastructure

HTML全文

参考文献(22)

[1]	Albhaisi S,Sanyal A.Recent advances in understanding and managing non-alcoholic fatty liver disease[J].F1000Res,2018,7.
[2]	孙超,范建高.中外非酒精性脂肪性肝病诊疗指南解读[J].中国实用内科杂志,2019,39(3):235-238.
[3]	Albillos A,de Gottardi A,Rescigno M.The gut-liver axis in liver disease:Pathophysiological basis for therapy[J].J Hepatol,2020,72(3):558-577.
[4]	Fang YL,Chen H,Wang CL,et al.Pathogenesis of non-alcoholic fatty liver disease in children and adolescence:From "two hit theory" to "multiple hit model"[J].World J Gastroenterol,2018,24(27):2974-2983.
[5]	McLean Wendy.The gut-liver axis:New therapeutic targets for non-alcoholic fatty liver disease[J].J Aus Tradit Med Soc,2019,25(1):54-62.
[6]	江澄,张涛.疏肝理脾方联合恩替卡韦治疗慢性乙型肝炎(肝郁脾虚证)的临床疗效[J].内蒙古中医药,2020,39(7):8-9.
[7]	王雅,张涛.中药治疗非酒精性脂肪性肝炎机制探讨[J].中西医结合肝病杂志,2019,29(5):480-482.
[8]	Kleiner DE,Brunt EM,Van Natta M,et al.Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J].Hepatology,2005,41(6):1313-1321.
[9]	中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(19):1706-1710.
[10]	崔翔,刘玲兰,华鹏,等.从脾论治非酒精性脂肪性肝病的体会与研究概况[J].中医临床研究,2020,12(14):136-138.
[11]	程贤文,张博,万文雅,等.脂肪性肝病中西医研究进展[J].中国中西医结合消化杂志,2019,27(4):318-322.
[12]	李春晓.非酒精性脂肪肝发病机制及中药治疗进展[J].光明中医,2020,35(12):4.
[13]	牙程玉,毛德文,王挺帅,等.非酒精性脂肪性肝病中西医研究进展[J].中西医结合肝病杂志,2021,31(2):188-192.
[14]	李敏谦,林育,项磊,等.基于临床文献的非酒精性脂肪性肝病证候分布规律研究[J].世界中医药,2019,14(1):6-11.
[15]	周漫,毛尔布,邱书香,等.非酒精性脂肪肝中医治疗组方规律的研究[J].西南医科大学学报,2021,44(1):59-62.
[16]	Jones RM,Neish AS.Redox signaling mediated by the gut microbiota[J].Free Radic Biol Med,2017,105:41-47.
[17]	Dai X,Wang B.Role of gut barrier function in the pathogenesis of nonalcoholic Fatty liver disease[J].Gastroenterol Res Pract,2015,2015:287348.
[18]	Akhmedov VA,Gaus OV.Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease[J].Ter Arkh,2019,91(2):143-148.
[19]	Safari Z,Gérard P.The links between the gut microbiome and non-alcoholic fatty liver disease(NAFLD)[J].Cell Mol Life Sci,2019,76(8):1541-1558.
[20]	Yang JM,Sun Y,Wang M,et al.Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease[J].World J Gastroenterol,2019,25(34):5105-5119.
[21]	Stalla FM,Astegiano M,Ribaldone DG,et al.The small intestine:barrier,permeability and microbiota.Key messages for clinicians[J].Minerva Gastroenterol Dietol,2020,Online ahead of print.
[22]	Taufiq A,Saputro RE,Yuliantika D,et al.Excellent antimicrobial performance of co-doped magnetite double-layered ferrofluids fabricated from natural sand[J].J King Saud Univ Sci,2020,32(7):3032-3038.